Search results for "Ethanolamine"

showing 10 items of 122 documents

Design, Synthesis, and Biological Evaluation of Novel Fluorinated Ethanolamines

2011

The preparation of novel fluorinated allylamines and their use as key fragments for the stereoselective synthesis of hydroxyethyl secondary amine (HEA)-type peptidomimetics is described. Our strategy employs chiral sulfinyl imines as synthesis intermediates, by treatment of hemiaminal precursors with two equivalents of vinylmagnesium bromide. The subsequent oxidation of the allylic amines to the corresponding epoxides was achieved by treatment with methyl(trifluoromethyl)dioxirane. Finally, epoxide ring opening with a range of nitrogen nucleophiles provided a library of HEA-derived peptidomimetics with a phenyldifluoromethylene moiety. The biological evaluation of these derivatives revealed…

Allylic rearrangementHalogenationPhthalic AcidsSulfonium CompoundsEpoxideCatalysisNocardiaantimicrobialsMycobacteriumchemistry.chemical_compoundDioxiraneNucleophileAnti-Infective AgentsfluorineMoietyOrganic chemistryAspartic Acid EndopeptidasesHumansEthanolamineTrifluoromethylMolecular StructureAntimicrobialsOrganic ChemistryEthanolaminesStereoisomerismBACE1FluorineGeneral ChemistrychemistryEthanolaminespeptidomimeticsHemiaminalethanolaminesEpoxy CompoundsIminesPeptidomimeticsAmyloid Precursor Protein Secretases
researchProduct

Development and validation of a liquid chromatography tandem mass spectrometry method for the analysis of beta-agonists in animal feed and drinking w…

2010

A reproducible, sensitive and selective multiresidue analytical method for seven beta-agonists: clenbuterol (CBT), clenpenterol (CPT), ractopamine (RTP), brombuterol (BBT), mabuterol (MBT), mapenterol (MPT), and hydroxymethylclenbuterol (HMCBT) was developed and validated by using liquid chromatography tandem mass spectrometry (LC-MS/MS) in feed and drinking water samples. The validation was achieved according to the criteria laid down in the Commission Decision 2002/657/EC, however it was necessary to use minimum required performance limits (MRPLs) proposed by the Community Reference Laboratories (CRLs) due to the lack of maximum residue limits (MRLs) for beta-agonists. By setting up these…

Animal feedBiochemistryHigh-performance liquid chromatographySensitivity and SpecificityAnalytical Chemistrychemistry.chemical_compoundLiquid chromatography–mass spectrometryTandem Mass SpectrometryWater SupplyPhenethylaminesSample preparationResidue (complex analysis)ChromatographyMabuterolOrganic ChemistryReproducibility of ResultsWaterGeneral MedicineAdrenergic beta-AgonistsAnimal FeedRactopaminechemistryEthanolaminesLinear ModelsWater qualityChromatography LiquidJournal of chromatography. A
researchProduct

Pharmacological blockade of the fatty acid amide hydrolase (FAAH) alters neural proliferation, apoptosis and gliosis in the rat hippocampus, hypothal…

2015

Endocannabinoids participate in the control of neurogenesis, neural cell death and gliosis. The pharmacological effect of the fatty acid amide hydrolase (FAAH) inhibitor URB597, which limits the endocannabinoid degradation, was investigated in the present study. Cell proliferation (phospho-H3(+) or BrdU(+) cells) of the main adult neurogenic zones as well as apoptosis (cleaved caspase-3(+)), astroglia (GFAP(+)), and microglia (Iba1(+) cells) were analyzed in the hippocampus, hypothalamus and striatum of rats intraperitoneally treated with URB597 (0.3 mg/kg/day) at one dose/4-days resting or 5 doses (1 dose/day). Repeated URB597 treatment increased the plasma levels of the N-acylethanolamine…

AstrocitosNeurobiologia del desenvolupamentAmidohidrolasasCannabinoid receptorCarbamatos:Chemicals and Drugs::Amino Acids Peptides and Proteins::Proteins::Intracellular Signaling Peptides and Proteins::Apoptosis Regulatory Proteins::Caspases [Medical Subject Headings]:Phenomena and Processes::Cell Physiological Phenomena::Cell Physiological Processes::Cell Differentiation::Neurogenesis [Medical Subject Headings]medicine.medical_treatment:Chemicals and Drugs::Carbohydrates::Monosaccharides::Hexoses::Glucose [Medical Subject Headings]Apoptosis:Phenomena and Processes::Physiological Phenomena::Body Constitution::Body Weights and Measures::Body Size::Body Weight [Medical Subject Headings]chemistry.chemical_compound:Chemicals and Drugs::Amino Acids Peptides and Proteins::Proteins::Membrane Proteins::Receptors Cell Surface::Receptors G-Protein-Coupled::Receptors Cannabinoid::Receptor Cannabinoid CB1 [Medical Subject Headings]0302 clinical medicine:Chemicals and Drugs::Organic Chemicals::Carboxylic Acids::Acids Acyclic::Carbamates [Medical Subject Headings]Fatty acid amide hydrolaseReceptor cannabinoide CB1:Organisms::Eukaryota::Animals [Medical Subject Headings]FAAHGliosishealth care economics and organizations:Chemicals and Drugs::Nucleic Acids Nucleotides and Nucleosides::Nucleosides::Deoxyribonucleosides::Deoxyuridine::Bromodeoxyuridine [Medical Subject Headings]:Chemicals and Drugs::Lipids::Glycerides::Triglycerides [Medical Subject Headings]Original Research0303 health sciencesNeurogenesisBenzamidas:Chemicals and Drugs::Polycyclic Compounds::Steroids::Cholestanes::Cholestenes::Cholesterol [Medical Subject Headings]Endocannabinoid systemEtanolaminas3. Good healthEndocannabinoides:Chemicals and Drugs::Lipids::Fatty Acids::Fatty Acids Unsaturated::Fatty Acids Monounsaturated::Oleic Acids [Medical Subject Headings]CannabinoidesMicroglíalipids (amino acids peptides and proteins)medicine.symptomColesterol:Chemicals and Drugs::Organic Chemicals::Hydrocarbons::Terpenes::Cannabinoids [Medical Subject Headings]:Chemicals and Drugs::Lipids::Fatty Acids::Palmitic Acids [Medical Subject Headings]psychological phenomena and processesProliferación celularmedicine.medical_specialtyCerebroNeurogenesiseducationBiologyBromodesoxiuridina:Anatomy::Nervous System::Neuroglia::Microglia [Medical Subject Headings]Triglicéridoslcsh:RC321-571Ácidos oléicosRatas03 medical and health sciencesCellular and Molecular NeuroscienceInternal medicineHipocampomedicineCaspasa 3:Anatomy::Nervous System::Central Nervous System::Brain::Limbic System::Hippocampus [Medical Subject Headings]:Phenomena and Processes::Cell Physiological Phenomena::Cell Physiological Processes::Cell Growth Processes::Cell Proliferation [Medical Subject Headings]lcsh:Neurosciences. Biological psychiatry. Neuropsychiatry030304 developmental biologyPalmitoylethanolamide:Chemicals and Drugs::Chemical Actions and Uses::Pharmacologic Actions::Molecular Mechanisms of Pharmacological Action::Neurotransmitter Agents::Endocannabinoids [Medical Subject Headings]:Chemicals and Drugs::Enzymes and Coenzymes::Enzymes::Hydrolases::Amidohydrolases [Medical Subject Headings]Cannabinoids:Anatomy::Cells::Neuroglia::Astrocytes [Medical Subject Headings]Peso corporalEnergy metabolism:Anatomy::Nervous System::Central Nervous System::Brain [Medical Subject Headings]:Anatomy::Nervous System::Central Nervous System::Brain::Limbic System::Hypothalamus [Medical Subject Headings]URB597:Phenomena and Processes::Cell Physiological Phenomena::Cell Physiological Processes::Cell Death [Medical Subject Headings]:Diseases::Pathological Conditions Signs and Symptoms::Pathologic Processes::Gliosis [Medical Subject Headings]:Chemicals and Drugs::Organic Chemicals::Amines::Amino Alcohols::Ethanolamines [Medical Subject Headings]Muerte celular:Phenomena and Processes::Cell Physiological Phenomena::Cell Physiological Processes::Cell Death::Apoptosis [Medical Subject Headings]:Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Rodentia::Muridae::Murinae::Rats [Medical Subject Headings]EndocrinologyURB597chemistryGliosisnervous systemGlucosaCannabinoidEnergy Metabolism:Chemicals and Drugs::Organic Chemicals::Amides::Benzamides [Medical Subject Headings]HipotálamoÁcidos palmíticos030217 neurology & neurosurgeryNeuroscienceFrontiers in Cellular Neuroscience
researchProduct

Varietal and geographic classification of french red wines in terms of elements, amino acids and aromatic alcohols

1988

Thirty-four French red wines from three regions already studied for their anthocyanin and flavonoid constituents have been further analysed for elements, amino acids and aromatic alcohols. An interpretation of the differences between wines related to their different geographic and varietal origins has been made from the results of statistical analyses: F statistic, principal component analysis (PCA) and stepwise discriminant analysis (SDA). Wine samples produced near Bordeaux were found to be characterised by higher rubidium and lower lithium and calcium concentrations. Differences between wine samples made from the same grape variety or produced in the same region are mainly related to dif…

Bordeaux wineFlavonoid01 natural scienceschemistry.chemical_compound0404 agricultural biotechnologyEthanolamine[SDV.IDA]Life Sciences [q-bio]/Food engineeringFood scienceChemical compositionComputingMilieux_MISCELLANEOUSWinechemistry.chemical_classificationNutrition and DieteticsChemistryStepwise discriminant analysisdigestive oral and skin physiology010401 analytical chemistryfood and beverages04 agricultural and veterinary sciences[SDV.IDA] Life Sciences [q-bio]/Food engineering040401 food science0104 chemical sciencesAmino acidAnthocyaninAgronomy and Crop ScienceFood ScienceBiotechnology
researchProduct

Budesonide/formoterol maintenance and reliever therapy: a new treatment approach for adult patients with asthma.

2007

An inhaled corticosteroid (ICS) or an ICS/long-acting beta(2)-agonist (LABA) combination plus short-acting beta(2)-agonist (SABA) as needed for symptom relief is recommended for persistent asthma. Additionally, budesonide/formoterol maintenance and reliever therapy (Symbicort SMART, AstraZeneca, Sweden) has been approved for adults in the European Union. This option is well tolerated and offers greater reductions in asthma exacerbations together with similar improvements in daily symptom control, at a lower overall steroid load, compared with fixed-dose ICS/LABA plus SABA.Two large clinical trials investigated the use of budesonide/formoterol as maintenance and reliever compared with medium…

BudesonideAdultMalemedicine.medical_specialtyAdolescentlaw.inventionPlacebosRandomized controlled trialDouble-Blind MethodlawInternal medicineFormoterol Fumaratemedicinemedia_common.cataloged_instanceHumansAnti-Asthmatic AgentsEuropean unionBudesonidemedia_commonAsthmaAgedRandomized Controlled Trials as TopicAged 80 and overbusiness.industryGeneral MedicineAdrenergic beta-AgonistsMiddle Agedmedicine.diseaseClinical trialTreatment OutcomeBudesonide/formoterolEthanolaminesPhysical therapyFormoterol FumarateDrug Therapy CombinationFemaleFormoterolbusinesshormones hormone substitutes and hormone antagonistsmedicine.drugCurrent medical research and opinion
researchProduct

Overall asthma control: the relationship between current control and future risk.

2009

Background Asthma guidelines emphasize both maintaining current control and reducing future risk, but the relationship between these 2 targets is not well understood. Objective This retrospective analysis of 5 budesonide/formoterol maintenance and reliever therapy (Symbicort SMART Turbuhaler ∗ ∗Symbicort SMART and Turbuhaler are trademarks owned by AstraZeneca. Neither the Symbicort SMART posology nor the dry powder formulation Turbuhaler are currently approved in the United States.) studies assessed the relationship between asthma control questionnaire (ACQ-5) and Global Initiative for Asthma-defined clinical asthma control and future risk of instability and exacerbations. Methods The perc…

BudesonideAdultMalemedicine.medical_specialtyExacerbationAdolescentImmunologyYoung AdultAdrenal Cortex HormonesInternal medicineFormoterol FumarateSurveys and QuestionnairesAdministration InhalationmedicineImmunology and AllergyBudesonide Formoterol Fumarate Drug CombinationHumansAnti-Asthmatic AgentsRisk factorBudesonideChildAsthmaAgedRandomized Controlled Trials as TopicRetrospective StudiesAged 80 and overInhalationbusiness.industryAdrenergic beta-AgonistsMiddle Agedmedicine.diseaseAsthmaMarkov ChainsDrug CombinationsAsthma Control QuestionnaireEthanolaminesChild PreschoolPractice Guidelines as TopicPhysical therapyFormoterol FumarateFemaleFormoterolbusinessmedicine.drugThe Journal of allergy and clinical immunology
researchProduct

Th17 immunity in children with allergic asthma and rhinitis: a pharmacological approach

2013

Th17 cells and IL-17A play a role in the development and progression of allergic diseases. We analyzed the IL-17A levels in sputum supernatants (Ss), nasal wash (NW) and plasma (P) from Healthy Controls (HC) and children with Asthma/Rhinitis. We tested the expression of IL-17A, RORγ(t) and FOXP3 in peripheral blood T-lymphocytes from intermittent and mild-moderate asthma. The effect of Budesonide and Formoterol was tested "in vitro" on IL-17A, RORγ(t) and FOXP3 expression in cultured T-lymphocytes from mild-moderate asthma/persistent rhinitis patients, and on nasal and bronchial epithelial cells stimulated with NW and Ss from mild-moderate asthma/persistent rhinitis. Further, the effect of …

BudesonideMalePulmonologyIL 13 and AsthmaGene ExpressionAnti-asthmatic AgentBiochemistryPediatricsimmune system diseasesFormoterol FumarateMolecular Cell BiologyAnti-Asthmatic AgentsBudesonideChildCells CulturedMultidisciplinaryImmune System ProteinsQInterleukin-17RFOXP3Forkhead Transcription FactorsNuclear Receptor Subfamily 1 Group F Member 3EthanolaminesMedicineFemaleInterleukin 17medicine.symptommedicine.drugResearch ArticleRhinitis Allergic PerennialAdolescentScienceImmunologyPediatric PulmonologyInflammationAdministration InhalationmedicineHumansAdrenergic beta-2 Receptor AgonistsBiologyAsthmaInflammationbusiness.industryInterleukin-8SputumImmunityProteinsImmunologic Subspecialtiesmedicine.diseaseNasal Lavage FluidAsthmarespiratory tract diseasesCase-Control StudiesImmunologySputumTh17 CellsClinical ImmunologyFormoterolbusinessPulmonary Immunology
researchProduct

Budesonide/formoterol for the treatment of asthma.

2003

Budesonide/formoterol (Symbicort), AstraZeneca plc) is a novel treatment for asthma, combining an inhaled corticosteroid - budesonide, and a long-acting beta(2)-agonist - formoterol, in a single inhaler, the Turbuhaler. Randomised, clinical studies in patients with asthma have demonstrated that budesonide/formoterol is more effective than the inhaled corticosteroids, budesonide and fluticasone alone, and at least as effective as both monocomponents in separate inhalers. Results from clinical studies suggest a synergistic effect when both drugs are administered via one inhaler, although the mechanisms for this are not fully understood. Budesonide/formoterol has a rapid onset of effect, appar…

Budesonideimmune system diseasesFormoterol FumaratemedicineHumansPharmacology (medical)Anti-Asthmatic AgentsBudesonideChildAsthmaFluticasonePharmacologyCOPDbusiness.industryInhalerDrug SynergismGeneral Medicinerespiratory systemmedicine.diseaseAsthmarespiratory tract diseasesDrug CombinationsBudesonide/formoterolEthanolaminesAnesthesiaFormoterol FumarateFormoterolbusinesshormones hormone substitutes and hormone antagonistscirculatory and respiratory physiologymedicine.drugExpert opinion on pharmacotherapy
researchProduct

Budesonide/formoterol for maintenance and reliever therapy in the management of moderate to severe asthma.

2008

The Global Initiative for Asthma (GINA) guidelines aim at improving asthma control and preventing future risk. For patients with moderate to severe asthma an inhaled corticosteroid (ICS) or an ICS/long-acting beta2-agonist (LABA) combination with a short-acting beta2-agonist (SABA) as reliever is recommended. Despite the availability of effective maintenance therapies, a large proportion of patients still fail to achieve guideline-defined asthma control, and overuse of SABA reliever medication at the expense of ICS is commonly observed. New simplified treatment approaches may offer a solution and assist physicians to achieve overall asthma control. One such treatment approach, which is reco…

Budesonidemedicine.medical_specialtyExacerbationImmunologySeverity of Illness IndexPharmacotherapyimmune system diseasesFormoterol FumarateSeverity of illnessAdministration InhalationmedicineImmunology and AllergyAnimalsHumansAnti-Asthmatic AgentsIntensive care medicineBudesonideAsthmaInhalationbusiness.industrymedicine.diseaseAsthmarespiratory tract diseasesBudesonide/formoterolEthanolaminesPhysical therapyDrug Therapy CombinationFormoterolbusinessmedicine.drugAllergy
researchProduct

Patterns of Innate or Acquired Resistance to Anticancer Drugs: Our Experience to Overcome It

2021

Drug resistance, which is often of a multiple type, can be defined as the ability of cancer cells to obtain resistance to both conventional and novel chemotherapy agents. It remains a major problem to solve in cancer therapy. The mechanisms of resistance are multifactorial, and in our cellular models of acute myeloid leukemia, hepatocellular carcinoma, and triple-negative breast cancer, it involves the NF-κB pathway. In our opinion, multitarget molecules can be considered as privileged compounds capable of attacking and reversing the resistant phenotype. In the phenomena of both innate and acquired drug resistance that we have been studying since 1998 to today and up to 2016 under the guida…

Cancer ResearchAntineoplastic AgentsApoptosisPhosphatidylethanolamine Binding ProteinDrug resistanceMetastasisBreast cancerdrug resistance P-glycoprotein IAP NF-κBNeoplasmsHumansMedicineATP Binding Cassette Transporter Subfamily B Member 1Transcription factorYY1 Transcription FactorP-glycoproteinbiologybusiness.industryKinaseNF-kappa BMyeloid leukemiamedicine.diseaseDrug Resistance NeoplasmCancer cellSettore BIO/14 - Farmacologiabiology.proteinCancer researchbusinessCritical Reviews™ in Oncogenesis
researchProduct